Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Neo-CheckRay: chemotherapy and SBRT with durvalumab and oleclumab in ER+/HER2- breast cancer

Alex De Caluwe • 14 Sep 2024
ESMO 2024
Breast Cancer Antibodies Checkpoint Inhibitors Durvalumab Oleclumab

Alex De Caluwe, MD, Jules Bordet Institute, Brussels, Belgium, gives an overview of the Phase II Neo-CheckRay trial (NCT03875573), which assessed chemotherapy with stereotactic body radiation therapy (SBRT) in patients with early-stage, high risk ER+/HER2- breast cancer. Patients were randomized to receive chemotherapy with SBRT alone, or with durvalumab, or with durvalumab and oleclumab. The primary and second endpoints include residual cancer burden (RCB) 0 -1 rates and pathological complete response respectively. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alex De Caluwe

Evaluating the emerging role of radiotherapy and immunotherapy in breast cancer
0:36
Evaluating the emerging role of radiotherapy and immunotherapy in breast cancer
Alex De Caluwe • 14 Oct 2024
Neo-CheckRay: safety findings of radiotherapy and immunotherapy in breast cancer
0:53
Neo-CheckRay: safety findings of radiotherapy and immunotherapy in breast cancer
Alex De Caluwe • 14 Sep 2024
Enhancing immunotherapy response in luminal B breast cancer with radiotherapy
1:08
Enhancing immunotherapy response in luminal B breast cancer with radiotherapy
Alex De Caluwe • 14 Sep 2024
Neo-CheckRay: boosting pCR rates in cold tumors
1:19
Neo-CheckRay: boosting pCR rates in cold tumors
Alex De Caluwe • 14 Sep 2024

Related Videos

HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
1:15
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
Sanjoy Chatterjee • 17 May 2026
Adherence to weight loss intervention in breast cancer patients
1:09
Adherence to weight loss intervention in breast cancer patients
Jennifer Ligibel • 31 May 2026
The content of VJOncology is intended for healthcare professionals